Conventional therapies including radiation therapy cannot cure squamous cell carcinoma (SCC), and new treatments are clearly required. Our recent studies have shown that SCC cell lines exhibiting radioresistance show significant upregulation of the fibroblast growth factor receptor 3 (FGFR3) gene. We hypothesized that inhibiting FGFR3 would suppress tumor cell radioresistance and provide a new treatment approach for human SCCs. In the present study, we found that RNA interference-mediated FGFR3 depletion in HSC-2 cells, a radioresistant cell line, induced radiosensitivity and inhibited tumor growth. Use of an FGFR3 inhibitor (PD173074) obtained similar results with suppression of the autophosphorylation extracellular signal-regulated kinase pathway in HSC-2 cells and lung cancer cell lines. Moreover, the antitumor growth effect of the combination of PD173074 and radiation in vivo was also greater than that with either drug alone or radiation alone. Our results provided novel information on which to base further mechanistic study of radiosensitization by inhibiting FGFR3 in human SCC cells and for developing strategies to improve outcomes with concurrent radiotherapy.
Introduction
Despite progress in radiation techniques, a significant proportion of patients who undergo irradiation to treat oral cancer develop local-regional recurrence or new primary cancers after completion of high-dose therapy. Patients undergoing radiotherapy for oral malignancies also develop painful mucositis, which often results in decreased oral intake, weight loss, decreased quality of life and unforeseen treatment interruptions. However, radiotherapy, especially intensity-modulated radiation therapy, is important, especially for patients with advanced disease (Studer et al., 2007) . Indicators, including biomarkers for genetic alterations, are needed to predict more accurately the outcome of radiotherapy for individual patients and to provide a novel therapy that inhibits/accelerates these genes.
Recently, our microarray analysis combined with the Ingenuity Pathway Analysis identified six genes (ID1, ID3, FGFR3, PEG10, ICAM2 and MMP13) associated with significant increases in radioresistant cells compared with radiosensitive cells in a dose-dependent and a time-dependent manner (Ishigami et al., 2007) . Of them, results with the fibroblast growth factor receptor 3 (FGFR3) gene, whose receptors regulate proliferation, differentiation, migration and apoptosis (Johnson and Williams, 1993; Friesel and Maciag, 1995) , emphasized the association with radioresistance based on the results of canonical pathway analysis, suggesting that the FGFR3 gene may disclose the molecular mechanisms of the radioresistance of squamous cell carcinomas (SCCs) that could be radiotherapeutic molecular markers for choosing the appropriate radiotherapy for this disease. The current work supported this speculation, because we identified FGFR3, the expression of which was associated with radioresistance in SCC cells. The current findings provided evidence that inhibiting the FGFR3 gene results in an enhanced radioresponse in human SCC cell lines in vitro and in vivo.
Results and discussion
To verify whether the FGFR3 gene is associated with radioresistance in vitro, we performed an small interfering RNA (siRNA) experiment to inhibit expression of FGFR3 in the HSC-2 (radioresistant) cell line, in which we previously reported that expression of FGFR3 was higher than in the HSC-3 (radiosensitive) cell line (Ishigami et al., 2007) . A series of cell growth experiments was performed to determine the effect of FGFR3 siRNA on the growth of the cancer cell lines. The growth curves of the HSC-2 cells showed that although treatment with FGFR3 siRNA significantly (Po0.01, Student's t-test) inhibited cell growth over 6 days, cell growth was not inhibited by vehicle and non-target control (siNT; Figure 1b) . Figure 1a shows the western blot analysis results of FGFR3 protein expression in HSC-2 cells 120 h after transfection with siRNAs. This time point was chosen by a positive silencing control test in an siRNA transfection experiment (data not shown). The FGFR3 protein expression level significantly decreased (Po0.01, Student's t-test) compared with nontransfected, vehicle-transfected and siNT-transfected cells.
We next determined the effect of radiosensitivity in FGFR3-knockdown HSC-2 cells. Figure 1c shows the radiation survival curves of untreated control cells and cells transfected with siRNAs. These data were used to calculate the dose of D 37 required to reduce survival to 37% (Toulany et al., 2006) . For the HSC-2 cells, the D 37 doses of the control, vehicle, siNT and siIFGFR3 were 6.4, 7.4, 6.0 and 4.3 Gy, respectively. Compared with the vehicle-treated controls, at the 37% survival level, the radiosensitivity of siFGFR3 cells was enhanced by a dose-modifying factor of 1.72 (D 37 values of vehicle/D 37 values of siFGFR3), and the radiosensitivity of cells was 1.23-fold (D 37 values of vehicle/D 37 values of siNT).
As stimulation of cell proliferation and differentiation by FGF receptors acts via activation of the extracellular signal-regulated kinase (ERK) pathway (Bar-Sagi and Feramisco, 1985; Noda et al., 1985) , we assessed the effect of a small-molecule FGFR inhibitor (PD173074) on ERK phosphorylation. Sequential increases in the /well in 24-well culture plates. Cells were transfected 24 h after plating with 100 nM siRNA targeting FGFR3 (OnTarget plus SMARTpool, Dharmacon, Lafayette, CO, USA; catalog no. L-003133-00) or non-targeting pool (OnTarget plus non-targeting pool no. 1, Dharmacon; catalog no. D-00181-01) using DharmaFect 1 (Dharmacon) for 3 days before the experiments. Cells were lysed in buffer (10 mM Tris base (pH 8.0), 400 mM NaCl, 3 mM MgCl 2 , 0.5% Nonidet P-40 (Sigma, St Louis, MO, USA), 100 mM phenylmethylsulfonyl fluoride and 0.01% protease inhibitor cocktail (Sigma) at 4 1C for 10 min. Protein extracts were separated by SDS-polyacrylamide gel electrophoresis in 11% gel, transferred to polyvinylidene fluoride membranes (Bio-Rad, Hercules, CA, USA) and blocked for 1 h at room temperature in 0.3% skimmed milk. The membranes were incubated with antibodies against rabbit anti-human FGFR3 polyclonal antibody (Abcam, Cambridge, UK) and mouse anti-human b-actin monoclonal antibody (Abcam) at 4 1C for overnight. The membranes were washed with 0.1% Tween-20 in TBS (TBS-T) and incubated with secondary antibodies, HRPconjugated anti-rabbit or anti-mouse IgG (Promega, Madison, WI, USA) for 1 h at room temperature. Finally, the membranes were incubated with the ECL þ kit (GE Healthcare, Buckinghamshire, UK), and immunoblotting was visualized by exposing the membrane to Hyperfilm (GE Healthcare). (b) To investigate the effect of FGFR3 siRNA on cell proliferation, siFGFR3-, non-targeting siRNAtransfected HSC-2 cells and vehicle cells were seeded in 12-well plates at a density of 1 Â 10 4 viable cells/well. The vehicle control cells were treated with only DharmaFECT1 reagent. At the indicated time points, the cells were trypsinized and counted using a hemocytometer in triplicate samples. The results represent the mean ± s.d. The asterisks indicate significant differences between siNT and siFGFR3 (*Po0.05, **Po0.01, Student's t-test). (c) The effect of radiation on the clonogenic survival of HSC-2 cells transfected with siRNAs. At 96 h after transfection, the cells were trypsinized and plated in 60-mm dishes for clonogenic survival assay for siFGFR3. After 24 h, when the cells had attached, they were irradiated with four single-radiation doses (2, 4, 6 and 8 Gy) using X-ray irradiation equipment (MBR-1520R-3; Hitachi, Tokyo, Japan) operated at 150 V and 20 mA with aluminum filtration, at a dose of 2.1 Gy/min. The colonies were stained with crystal violet (Sigma), and colonies of 50 cells or greater were counted. Clonogenic fractions of irradiated cells were normalized to the plating efficiency of unirradiated controls. Each experiment was repeated at least three times; the error bars represent ± s.d. The significance of the difference between siNT (triangles) and siFGFR3 (circles) is indicated by asterisks (*Po0.05, **Po0.01, Student's t-test).
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K Uzawa et al PD173074 concentration led to decreased phosphorylation of ERK at 1, 3 and 6 h after treatment (Figure 2 ), indicating that the effect of PD173074 in cells continued from 1-6 h. Therefore, we performed the rediosensitivity assay at 3 h after PD173074 treatment. PD173074 (100 nM) also inhibited cell growth compared with the control cells ( Figure 3a ). Similar to the results of the siRNA experiment, enhanced radiosensitivity was detected in HSC-2 cells treated with PD173074 ( Figure 3b ). For PD173074-treated HSC-2 cells, the D 37 dose of the control, dimethyl sulfoxide and 5, 25 and 100 nM of PD173074 were 5.68, 5.63, 5.43, 3.63 and 3.89 Gy, respectively. Compared with the dimethyl sulfoxide-treated controls, at the 37% survival level, the radiosensitivity of cells treated with 100 nM PD173074 was enhanced by a dose-modifying factor To further analyze the effect of PD173074 on other types of human cancer cells, we used human lung cancer cells, HARA and A549. Similar to the HSC-2 cells, PD173074 enhanced the radiosensitivity in both the cell lines (Figures 3c and d) .
We then determined whether PD173074 affected the tumor response to radiotherapy. The HSC-2 cells were inoculated subcutaneously into female athymic nude mice and allowed to grow to a mean volume of 100 mm 3 . The response to the HSC-2 xenografts to radiation plus PD173074 was enhanced significantly (Po0.01, Student's t-test) compared with controls and systemic therapy with radiation alone, PD173074 alone (Figure 4a ). Treatment with systemic PD173074 reduced the mean tumor volume by 39.9% (1523.5±257.8 mm 3 compared with 2535 ± 437.5 mm 3 in the control group; n ¼ 5; Figure 4a ). Similarly, treatment with only radiation reduced the mean tumor volume by 57.9% (1066.2 ± 101.7 mm 3 compared with 2535 ± 437.5 mm 3 in the control group; n ¼ 5; Figure 4a ). Systemic PD173074 combined with radiation resulted in consistently smaller tumors than in control animals, with the tumor volume reduced by about 90% (242.2 ± 116.6 mm 3 compared with 2535±437.5 mm 3 in the control group; n ¼ 5, Po0.01; Figure 4a ).
Although considerable evidence has suggested that mutations in the FGFR3 gene are associated with severe skeletal dysplasia (Eswarakumar et al., 2005) , abnormalities of this gene leading to its overexpression also have been identified in a variety of human cancers, including multiple myeloma and glioblastoma, and bladder, prostate, cervix and breast cancers (Chesi et al., 1997; Eswarakumar et al., 2005; Rosty et al., 2005; Knowles, 2008) . These findings strongly suggested the oncogenic properties of the FGFR3-mutated receptor. FGFR3, an elevated mRNA expression level of which was detected in radioresistant human SCC cell lines in our previous study (Ishigami et al., 2007) , was found to be a candidate for radioresistant enhancements in SCC cells using microarray analysis. A more recent study also reported a relationship between FGFR3 and radiation sensitivity in artificially FGFR3-reduced oral SCC cells 
K Uzawa et al (Henson and Gollin, 2010) . To date, no studies have been published on the functional significance of radiation sensitivity by inhibition of FGFR3 expression. The current study thus was designed to further examine whether FGFR3 is functionally associated with the radiosensitivity of human SCC cells in vitro and in vivo. Downregulation of FGFR3 in HSC-2 cells induced significant radiosensitivity in vitro, which indicated the important role of FGFR3 in the radioresistant SCC cells. Another important point is that radiosensitization of cells may depend on the degree of FGFR3 protein inhibition. Because HSC-2 cells were incubated for a longer time with siFGFR3, they became more radiosensitive (Figure 1c) , suggesting that radiosensitization of HSC-2 cells may be determined by the amount of FGFR3 protein in the cells at the time of irradiation. PD173074, the pharmacological FGFR inhibitor, is a synthetic compound of the pyrido(2,3-d)pyrimidine class that inhibits tyrosine kinase activities and inhibits several FGFR families including FGFR3 in human cancer cells (Koziczak et al., 2004; Trudel et al., 2004) . In addition, because FGFR3 signals partly through the Ras/mitogen-activated protein kinase pathway (MasihKhan et al., 2006), we assessed the effect of the inhibitors on ERK phosphorylation. In response to treatment with PD173074, the radioresistant cell line (HSC-2) underwent radiosensitization with decreased phosphorylation of ERK (Figure 2) . It is also noteworthy that the previously mentioned chemical effect was observed in a different set of lung cancer cell lines.
These results suggested that FGFR3 may regulate radioresistance in human cancer cells by activation of the Ras/mitogen-activated protein kinase pathway, resulting in upregulation of a number of critical genes.
Most importantly, our in vitro results were reproduced in vivo. Although the antitumor effects were limited with the doses of radiation administered and PD173074 administered alone, tumor growth was inhibited markedly when the treatments were combined (Figure 4a) . Cell proliferation and apoptosis can regulate the tumor size at any given time. Therefore, we performed immunohistochemistry in tumor tissues to measure the proliferating cell nuclear antigen expression and the terminal deoxynucleotidyl transferase-mediated 2 0 -deoxyuridine, 5 0 -triphosphate-biotin nick-end labeling assay to measure apoptosis. As shown in Figures 4a  and b , decreased proliferation (proliferating cell nuclear antigen) and enhanced apoptosis (terminal deoxynucleotidyl transferase-mediated 2 0 -deoxyuridine, 5 0 -triphosphate-biotin nick-end labeling) were most pronounced in the combination-treated group (average proliferating cell nuclear antigen and terminal deoxynucleotidyl transferase-mediated 2 0 -deoxyuridine, 5 0 -triphosphate-biotin nick-end-labeling-positive staining cells were 47.2±3.0 and 7.6 ± 2.3 for control, 30.6 ± 5.2 and 17.3 ± 4.3 for PD173074 alone, 27.6 ± 4.5 and 18.8 ± 5.9 for radiation alone, and 6.8±3.3 and 33.2±5.9 for combination, respectively; Po0.05). Thus, our findings suggest that the enhanced radiosensitizing effects, observed when PD173074 is combined with radiation, are attributable, in Figure 4 (a) Antitumor activity of PD173074 combined with radiation in HSC-2 cell line xenografts. The HSC-2 cells were injected subcutaneously into the lower limb of female athymic nude mice, BALB/cAnNcrj-nu/nu, purchased from Charles River Japan Inc. (Yokohama, Kanagawa, Japan). The care and treatment of experimental animals were in accordance with institutional guidelines. Mice were injected in the lower limb subcutaneously with 2 Â 10 7 HSC-2 (radioresistant) cells. When the volume of transplantation tumor reached 100 mm 3 , 10 mice/group were treated with PD173074 (25 mg/kg intraperitoneally on days 0-4 each week for 2 weeks) and/or radiation (4 Gy on days 0-4 each week for 2 weeks). The animal experiments included four treatment groups: control (n ¼ 5), PD173074 alone (n ¼ 5), radiation alone (n ¼ 5) and radiation combined with PD173074 (n ¼ 5). Caliper measurements of the longest perpendicular tumor diameters were performed on alternate day to estimate the tumor volume using the following formula: 4p/3 Â (width/2) 2 Â (length/2). After the volume of transplantation tumor reached 100 mm 3 , the mice were treated with PD173074 (25 mg/kg intraperitoneally on days 0-4 each week for 2 weeks) and/or radiation (4 Gy on days 0-4 each week for 2 weeks). The values represent the mean tumor size±s.e.m. (n ¼ 5/group). **Po0.01, Student's t-test, compared with respective control. Effects of PD173074 combined with radiation on tumor cell proliferation and apoptosis. The tumor tissues, derived from four groups: control, PD173074 alone, radiation alone and radiation combined with PD173074, were fixed in 10% formalin, and paraffin sections (4 mm) were prepared for hematoxylin and eosin (H&E) staining, immunohistochemistry of proliferating cell nuclear antigen (PCNA) and the terminal deoxynucleotidyl transferase-mediated 2 0 -deoxyuridine, 5 0 -triphosphate (dUTP)-biotin nick-end labeling (TUNEL) assay. For PCNA, tissue sections were stained with primary antibody against PCNA (Abcam). Briefly, after deparaffinization and hydration, the endogenous peroxidase activity was quenched by 30-min incubation in a mixture of 0.3% hydrogen peroxide solution in 100% methanol, after which the sections were blocked for 2 h at room temperature with 1.5% blocking serum (Santa Cruz Biotechnology) in phosphate-buffered saline (PBS) before reaction with anti-PCNA antibody (1:100 dilution) at 37 1C in a moist chamber overnight. Upon incubation with the primary antibody, the specimens were washed three times in PBS and treated with Envision reagent (DAKO, Carpinteria, CA, USA), followed by color development in 3,3 0 -diaminobenzidine tetrahydrochloride (DAB, DAKO). The slides then were dehydrated with ethanol, cleaned with xylene and mounted. Nonspecific binding of an antibody to proteins other than the antigen sometimes occurred. As a negative control, triplicate sections were immunostained without exposure to primary antibodies, which confirmed the staining specificity. TUNEL staining was performed using an ApopTag Peroxidase in situ Apoptosis Detection Kit (S7100, Chemicon, Billerica, MA, USA) and visualized using DAB according to the manufacturer's instructions. Original magnification Â 400. (b) Quantification of PCNA-and TUNEL-positive cells. Tumor slides of different groups were visualized under microscope, and PCNA-and TUNEL-positive cells were quantified. Results were expressed as the number of PCNA-or TUNELpositive cells/field counted (five random fields per slide from a total of five slides per study group, magnification Â 100). Data represent mean±s.e.m. The asterisks indicate significant difference from respective controls (*Po0.05, Student's t-test). (c) Athymic nude mice without injection of oral cancer cells were randomly placed into either a vehicle control group (dimethyl sulfoxide) or a group treated with PD173074. Body weight were measured throughout the 35 days of treatment (upper panel) . Values shown represent the mean ± s.e.m. (n ¼ 5/group). Acute skin reactions on the lower limb of mice (lower panel) treated with radiation-only and radiation plus PD173074 were assessed using an arbitrary scoring system (Fowler et al., 1974) . The scoring system comprised 8 degrees, from 0 to 3.5. The values represent the mean skin reaction score ± s.e.m. (n ¼ 5/group).
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We have found that the average body weight of the mice in the PD173074 treatment group never became lower than that of the control group (radiation-only) at any point of the experiment (Figure 4c ). No significant difference of skin reaction during irradiation treatment was also detected between radiation-only group and radiation plus PD173074 group (Figure 4c) . In addition to our results, a recent study has reported that oral PD173074 is available, and no toxicity was observed in treated mice (Pardo et al., 2009) . Therefore, these results further support our hypothesis that FGFR3 is an important target in overcoming de novo and acquired radioresistance in human SCCs. Taken together, these data suggested that FGFR inhibition could provide a powerful radiotherapeutic strategy for treating SCC in clinical settings. The therapeutic potential of PD173074 in the radiation treatment of SCC has led to development of promising strategies to deliver PD173074 in vivo.
Although previous studies have reported an association between enhanced radiosensitivity in oral SCC and certain gene expression (Shintani et al., 2003; Ishigami et al., 2007) , to the best of our knowledge, the current report is the first on the use of the combination of an FGFR3 inhibitor and radiation in vitro and in vivo. Finally, the current data supported the idea that combination therapy with radiation and an FGFR3 inhibitor increases the therapeutic efficacy of radiation in human cancers including SCCs.
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